Case Report: Chanarin-Dorfman Syndrome: A Novel Homozygous Mutation in ABHD5 Gene in a Chinese Case and Genotype-Phenotype Correlation Analysis

Bo Liang1,2,3,4,5,6, He Huang1,3,4,5,6, Jiaxiang Zhang7, Gang Chen1,3,4,5,6, Xiangsheng Kong8, Mengting Zhu9, Peiguang Wang1,3,4,5,6 and Lili Tang1,3,4,5,6*

1Department of Dermatology and Venereology, The First Affiliated Hospital, Anhui Medical University, Hefei, China, 2Department of Clinical Laboratory, The First Affiliated Hospital, Anhui Medical University, Hefei, China, 3Institute of Dermatology, Anhui Medical University, Hefei, China, 4Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, China, 5State Key Laboratory Incubation Base of Dermatology, Anhui Medical University, Hefei, China, 6Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China, 7Department of Occupational Health and Environment Health, School of Public Health, Anhui Medical University, Hefei, China, 8Aberlong Biological Technology Co., Ltd., Shanghai, China, 9Department of Clinical Medical, the First Clinical Medical College, Anhui Medical University, Hefei, China

The Chanarin–Dorfman syndrome (CDS) is a rare, autosomal recessively inherited genetic disease, which is associated with a decrease in the lipolysis activity in multiple tissue cells. The clinical phenotype involves multiple organs and systems, including liver, eyes, ears, skeletal muscle and central nervous system. Mutations in ABHD5/CGI58 gene have been confirmed to be associated with CDS. We performed whole exome sequencing on a Chinese CDS patient with skin ichthyosis features mimicking lamellar ichthyosis, ectropion, sensorineural hearing loss, and lipid storage in peripheral blood neutrophils. A novel homozygous missense mutation (p.L154R) in ABHD5 gene was detected in this patient. Genotype-phenotype analysis in reported CDS patients revealed no particular correlation. Our findings further enrich the reservoir of ABHD5 mutations in CDS.

Keywords: ichthyosis, ABHD5/CGI-58 gene, Chinese, Jordan’s anomaly, Chanarin-Dorfman syndrome

INTRODUCTION

Chanarin-Dorfman syndrome (CDS; OMIM 275630) is an extremely rare, multisystemic, autosomal recessive neutral lipid storage disorder (NLSD) arising from impaired lipid metabolism (Demerjian et al., 2006). CDS is associated with a multitude of clinical symptoms, the most prominent of which is ichthyosis, especially non-bullous congenital ichthyosiform erythroderma. Patients can be born as collodion babies, occasionally accompanied by bilateral ectropion and eellabion. Other manifestations include liver steatosis, myopathy, sensoryneural hearing loss, and cataract (Yamaguchi and Osumi, 2009). To date, approximately 120 cases of CDS have been reported around the world, but mainly in Mediterranean and Middle Eastern countries, especially in Turkey (Incecik et al., 2018; Eskiocak et al., 2019; Louhichi et al., 2019; Niculescu et al., 2019; Al-Hage et al., 2020; Dabas et al., 2020; Cakmak and Bagci, 2021; Jiang et al., 2021; Tavian et al., 2021). So far, only three patients of CDS have been reported from China (Takeichi et al., 2016; Jiang et al., 2021).

CDS is caused by mutations of the abhydrolase domain containing 5 gene (ABHD5)/comparative gene identification-58 (CGI-58) on chromosome 3p21, leading to insufficient fatty acids (FAs)
mobilization within the cell and systemic triglyceride accumulation in cytosolic droplets in multiple tissues. These lipid droplets have been observed in hepatocytes, intestinal mucosa, blood, bone marrow, skin fibroblasts, myocytes, central nervous system cells and many other types of cells.

The diagnosis is based on the presence of ichthyosis and identification of lipid droplets in granulocytes (Jordan’s anomaly) in peripheral blood smear. For patients with CDS, dietary modification has been reported to be an effective treatment, with no deleterious effects on liver function (Kakourou et al., 1997). Herein, we present a Chinese patient with CDS caused by a novel homozygous missense mutation, p.L154R, in ABHD5 gene, and the genotype-phenotype correlation analysis was also conducted.

MATERIALS AND METHODS

Case Report

The proband (IV2) in this study was a 30-year-old female displaying diffuse erythema, fine scaling on the body, and sensorineural hearing loss since her birth as a collodion baby. The severity of the ichthyosiform erythroderma had lessened as she aged. The condition was severe in winter and mild in summer. Her nails, teeth and hair appeared normal. No additional involvement of muscular system and central nervous system was found. Her parents were consanguineous (first cousins), and there were no other affected family members. Her son was 1 year old and was normal (Figure 1).

Physical examinations of the proband revealed coarse facial features, including ptosis, bilateral extropion of the eyelids, broad forehead, depressed nasal bridge, and extensive erythematos patch and plaques accompanied by fine scaling covering the body (Figures 2A,B). Dermatoscopy showed dilatation of twisted capillaries and diffused white scales (Figure 2C). Laboratory findings revealed high levels of alanine aminotransferase (ALT, 108 U/L; normal 7–40 U/L), aspartate aminotransferase (AST, 87 U/L; normal 13–35 U/L), creatine kinase (CK, 400 U/L; normal 100–250 U/L), and low levels of urea (2.42 mmol/L;
PERIPHERAL BLOOD COLLECTION AND DNA EXTRACTION

After obtaining informed consent from all participants and approval from Clinical Research Ethics Committee of Anhui Medical University, EDTA anticoagulated venous blood samples were collected from the family. Genomic DNA was extracted using a Flexi Gene DNA Kit (250) in a standard procedure and stored at −80°C. The procedures were in accordance with the Helsinki Declaration of 1975, as amended in 1983.

WHOLE EXOME SEQUENCING

WES was performed in the proband (IV2). Genomic DNA fragments corresponding to all exons in genome were amplified by PCR and subjected to automatic DNA sequencing after purification. Agilent SureSelect XT Library Prep Kit and SureSelect Human All Exon V6 kit were used for the library preparation and capture. Illumina Hiseq XTen platform was used for the sequencing. Screening for disease-associated deleterious mutations was made with emphasis on all the possible pathogenic variations in reported ABHD5 gene.

SANGER SEQUENCING

The possible pathogenic variations identified by WES were confirmed by Sanger sequencing in the proband’s father (III2) and sister (IV1) to detect genotype-phenotype co-segregation. Primers flanking all coding regions of the possible variation were designed using software Primer Premier 5.0 (Primer Biosystems, Foster City, CA, United States). PCR products from genomic DNA were sequenced using an ABI 3730XL DNA Analyzer (ABI, Foster City, CA, United States). The sequencing results were analyzed using Finch TV (Version 1.5), and the newly discovered mutation was named referring to the principle of the Human Genome Variation Society (HGVS).

REVIEW OF THE LITERATURE

Articles published between 1974 and 2021 were searched on PubMed by using the following keywords singly or in various combinations: “Chanarin–Dorfman Syndrome”, “Dorfman–Chanarin syndrome”, “congenital ichthyosiform erythroderma”, “neutral lipid storage disorder”, “ABHD5/CIGS8 mutation” and “Jordan’s anomaly”. The patients’ race, age, gender, clinical symptoms, genetic mutations were all evaluated.

RESULTS

WES RESULTS AND CO-SEGREGATION ANALYSIS

WES revealed a novel homozygous missense mutation c.461T>G (NM_016006) in ABHD5 gene, resulting in the substitution of amino acid arginine for leucine at position 154 (p.L154R), which is a highly conserved amino acid leucine across multiple species (Figures 3A,B). The mutation was predicted by REVEL to be pathogenic and by SIFT to be damaging, with scores of 0.959 and 0, respectively. Sanger sequencing revealed the mutation was homozygous in the proband and heterozygous in her father and sister. (Figure 3A). The mutation was not found in 100 control individuals from the same ethnicity, and was not recorded in the database of genomAD.

GENOTYPE-PHENOTYPE CORRELATION ANALYSIS

We found 106 CDS patients (58 male) reported in literature in whom the molecular analysis of ABHD5 gene were performed (Supplementary Table S1). The age of the patients varied from 4 months to 67 years. A total of 45 mutations in ABHD5 have been identified, including 37 homozygous mutations and 8 compound heterozygous mutations (Supplementary Table S1). The mutations identified in the patients included missense, nonsense, insertions, deletions, and frameshift mutations. Irrespective the nature of the mutation, all CDS patients showed the typical skin features of non-bullous congenital ichthyosiform erythroderma and Jordan’s anomaly, followed by hepatomegaly and hepatosteatosis. The most common mutation in patients is p. N209X (26/45, 57.8%). Within the group of N209X mutation patients, the CDS phenotype was homogeneous. This mutation was identified in 26 cases (23 from Turkey), and is rare in other populations. The other mutations mostly appear to be familial or local. No particular genotype-phenotype correlation were found in the literature.

DISCUSSION

In the present study, the clinical features, laboratory findings and genetic results of the proband were consistent with the diagnosis of CDS. And mutation analysis of ABHD5 using WES and Sanger sequencing revealed a new homozygous mutation. For this mutation, p. L154R, leucine is a hydrophobic amino acid, while arginine is an alkaline amino acid. The transition of the amino acid polarity may affect the structure and function of ABHD5 protein.

To date, 45 different mutations in the ABHD5 gene have been reported (Incecik et al., 2018; Eskiocak et al., 2019; Louhihi et al., 2019; Niculescu et al., 2019; Al-Hage et al., 2020; Dabas et al., 2020; Cakmak and Bagci, 2021; Jiang et al., 2021; Tavian et al., 2021), among which the homozygous mutation of p. N209X is the most common. A comparison of findings in patients with the common N209X mutation and other mutations did not show major differences, and does not point to a particular genotype-phenotype correlation, which is consistent with previous researches (Aggarwal et al., 2012; Nur et al., 2015). The variability of clinical symptoms in patients with CDS depends on a large number of mutations involved, and the severity of the phenotype can be quite variable. Ichthyosis from birth was a universal presentation, followed by liver disease. It is reported that there was an intrafamilial
phenotypic heterogeneity in the alive affected individuals, which led to the hypothesized that mutations in other genes might have affected the phenotypes through modifier effects (Takeichi et al., 2016). Furthermore, the lack of correlation between the genotype and the severity of the disease may be explained by the role of epigenetic and environmental factors. Liver involvement is an important cause of mortality and morbidity in CDS patients. Most of the patients with cirrhosis identified in the literature had advanced age (Cakmak and Bagci, 2021). However, it is reported that the cirrhosis may develop at an early age depending on the nature of the mutations (Aggarwal et al., 2012; Tamhankar et al., 2014). So, it is possible that there is some genotype-phenotype correlation. More CDS cases with mutation data are needed to confirm the genotype-phenotype correlations in ABHD5 mutations.

Mutations in ABHD5 may lead to the accumulation of long-chain fatty acids, energy deficiency in cells and affect the skin barrier (Tamhankar et al., 2014). The ABHD5 protein has been studied as a cofactor for adipose triglyceride lipase (ATGL). Ujihara er al. revealed that the triglycerides levels in the scales from the patient were positively correlated with the severity of ichthyosis (Ujihara et al., 2010). The level of triglyceride in this patient was normal, which may be a reason for the mild clinical manifestation of this patient. It has been shown that ABHD5 participates in the assembly and release of hepatitis C virus particles by mobilizing the lipid pool of cytoplasmic lipid droplets, therefore, CDS patients may show certain resistance to hepatitis C virus infection (Vieyres et al., 2016).

The diagnosis of CDS can be confirmed by performing a peripheral blood smear to show lipid vacuoles in granulocytes, myocytes, hepatocytes, fibroblasts and keratinocytes, a feature called Jordan’s anomaly. Ichthyosiform erythroderma, as a usual symptom of CDS, is a typical manifestation in congenital ichthyosis syndromes. Studies found that the co-existence of Jordan’s anomaly and ichthyosis provided the definitive diagnosis in CDS, regardless of the ABHD5 gene mutation (Cakmak and Bagci, 2021). Therefore, PBS is necessary to examine for the presence of Jordan’s anomaly. In peripheral blood smears taken from our patients, lipid vacuolization was seen in the cytoplasm of leukocytes. This finding supports the presence of a natural lipid storage disorder.

There has been no curative treatment of CDS so far. Various topical therapies, including emollients and keratolytic agents, have been proposed to improve ichthyosis, with mostly unsatisfactory results. While systemic therapy with retinoids combined with dietary modification has been used successfully in patients with skin and muscle manifestations (Gandhi et al., 2007; Israeli et al., 2012), co-morbidities limit its use in CDS. Niculescu et al. proposed tazarotene 0.015% cream as a potential topical agent for patients with ichthyosis, including patients with systemic involvement (Niculescu et al., 2019). In the present study, a diet low in fat and rich in short/medium-chain fatty acids and emollients were administered. After 1 year
of treatment, the skin lesions improved, and the patient was satisfied with the treatment effect and attended the scheduled follow-up visits.

In conclusion, the patient we presented showed ichthyosiform dermatosis, and mutation analysis eventually confirmed the diagnosis of CDS. CDS presents suffer from damage of many systems, and the severity of the phenotype can be quite variable. The diagnosis can be established by the clinical features and a blood smear, which can be confirmed by the molecular analysis. The mutation found in this patient enriched our understanding of pathogenic mutations for CDS. As it is not easy to obtain an accurate diagnosis only based on the dermal features, a blood smear and mutational analysis are required for patients suspected with congenital ichthyosis (Cheng et al., 2020).

**DATA AVAILABILITY STATEMENT**

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Clinical Research Ethics Committee of Anhui Medical University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

Aggarwal, S., Maras, J. S., Alam, S., Khanna, R., Gupta, S. K., and Ahuja, A. (2012). Novel Nonsense Mutation of ABHD5 in Dorfman-Chanarin Syndrome with Unusual Findings: a challenge for Genotype-Phenotype Correlation. *Eur. J. Med. Genet.* 55 (3), 173–177. doi:10.1016/j.ejmg.2012.01.013

Al-Hage, J., Abbas, O., Nemer, G., and Kurban, M. (2020). Chanarin-Dorfman Syndrome: a Novel Homozygous Mutation in the ABHD5 Gene. *Clin. Exp. Dermatol.* 45 (2), 257–259. doi:10.1111/ced.14062

Cakmak, E., and Bagci, G. (2021). Chanarin-Dorfman Syndrome: A Comprehensive Review. *Liver Int.* 41 (5), 905–914. doi:10.1111/liv.14794

Cheng, R., Liang, J., Li, Y., Zhang, J., Ni, C., Yu, H., et al. (2020). Next-generation Sequencing through Multi-genie Panel Testing for Diagnosis of Hereditary Ichthyosis in Chinese. *Clin. Genet.* 97 (5), 770–778. doi:10.1111/cge.13704

Dabas, G., Mahajan, R., De, D., Handa, S., Kumar, R., Dayal, D., et al. (2020). Managing Syndromic Congenital Ichthyosis at a Tertiary Care Institute: Genotype-phenotype Correlations, and Novel Treatments. *Dermatol. Ther.* 33 (6), e13816. doi:10.1111/dth.13816

Demerjian, M., Crumrine, D. A., Milstone, L. M., Williams, M. L., and Elias, P. M. (2006). Barrier Dysfunction and Pathogenesis of Neutral Lipid Storage Disease with Ichthyosis (Chanarin-Dorfman Syndrome). *J. Invest. Dermatol.* 126 (9), 2032–2038. doi:10.1038/sj.jid.5703322

Eskiocak, A. H., Missaglia, S., Moro, L., Durdu, M., and Taviani, D. (2019). A Novel Mutation of ABHD5 Gene in a Chanarin Dorfman Patient with Unusual Dermatological Findings. *Lipids Health Dis.* 18 (1), 232. doi:10.1186/s12944-019-1181-6

**AUTHOR CONTRIBUTIONS**

BL conducted Sanger sequencing and wrote the manuscript. HH and JZ performed whole exome sequencing and wrote the manuscript. GC, XK, and MZ collected clinical data and blood samples, and performed DNA extraction. LT performed data analysis of the whole exome sequencing. PW and LT were responsible for the study design and guiding of the study implementation, and revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the Open Fund of Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education, P.R. China (Anhui Medical University) (No.KFJJ-2021-10), and the Fund of Anhui Provincial Institute of Translational Medicine (No.2021zhyx-C31).

**ACKNOWLEDGMENTS**

We are most grateful to all the participants for participating in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.847321/full#supplementary-material

Gandhi, V., Aggarwal, P., Dhawan, J., Singh, U., and Bhattacharya, S. (2007). Dorfman-Chanarin Syndrome. *Indian J. Dermatol. Venereol. Leprol.* 73 (1), 36–39. doi:10.4103/0378-6323.30650

Incecik, F., Herguner, O. M., Ozbek, M. N., Gungor, S., Yilmaz, M., Rizzo, W. B., et al. (2018). Neuro-ichthyotic Syndromes: A Case Series. *J. Pediatr. Neurosci.* 13 (1), 34–38. doi:10.4103/JPN.JPN_54_17

Israel, S., Pessah, Y., Sarig, O., Goldberg, I., and Sprecher, E. (2012). Beneficial Effect of Acitretin in Chanarin-Dorfman Syndrome. *Clin. Exp. Dermatol.* 37 (1), 31–33. doi:10.1111/j.1365-2230.2011.04164.x

Jiang, X., Zhong, W., Yu, B., Lin, Z., and Wang, H. (2021). Two Cases of Chanarin-Dorfman Syndrome with Novel and Recurrent Mutations in the ABHD5 Gene. *Int. J. Dermatol.* 60 (7), 904–906. doi:10.1111/ijd.15432

Kakourou, T., Drogari, E., Christomanou, H., Giannoulia, A., and Dacou-Voutetakis, C. (1997). Neutral Lipid Storage Disease-Response to Dietary Intervention. *Arch. Dis. Child.* 77 (2), 184. doi:10.1136/adc.77.2.183c

Louhichi, N., Bahliouh, E., Marrakchi, S., Othman, H. B., Triki, C., Aloulou, K., et al. (2019). Thyroid Involvement in Chanarin-Dorfman Syndrome in Adults in the Largest Series of Patients Carrying the Same Founder Mutation in ABHD5 Gene. *Orphanet J. Rare Dis.* 14 (1), 112. doi:10.1186/s13023-019-1095-4

Niculescu, L., Rumi, C., Sour, J., Salzer, S., Schönbucher, J., von Braumühl, T., et al. (2019). Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome. *Acta Derm Venereol.* 99 (3), 345–346. doi:10.2340/00015555-3087

Nur, B. G., Gencpinar, P., Yuzbasoglu, A., Emre, S. D., and Mihić, E. (2015). Chanarin-Dorfman Syndrome: Genotype-phenotype Correlation. *Eur. J. Med. Genet.* 58 (4), 238–242. doi:10.1016/j.ejmg.2015.01.011

Takeichi, T., Sugihara, K., Tso, S., Simpson, M. A., McGrath, J. A., and Akiyama, M. (2016). Bi-allelic Nonsense Mutations in ABHD5 Underlie a Mild Phenotype of
Conflict of Interest: Author XK is employed by Aberlong Biological Technology Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.